- Report
- January 2026
- 183 Pages
Global
From €3179EUR$3,545USD£2,716GBP
€3532EUR$3,939USD£3,018GBP
- Report
- October 2025
Global
From €4393EUR$4,900USD£3,754GBP
- Report
- August 2025
Global
From €4393EUR$4,900USD£3,754GBP
- Report
- February 2026
- 250 Pages
Global
From €4026EUR$4,490USD£3,440GBP
- Report
- February 2026
- 250 Pages
Global
From €4026EUR$4,490USD£3,440GBP
- Report
- February 2026
- 250 Pages
Global
From €4026EUR$4,490USD£3,440GBP
- Report
- February 2026
- 250 Pages
Global
From €4026EUR$4,490USD£3,440GBP
- Report
- August 2026
- 378 Pages
Global
From €5245EUR$5,850USD£4,482GBP
- Report
- August 2026
- 390 Pages
Global
From €5245EUR$5,850USD£4,482GBP
- Report
- August 2026
- 287 Pages
Global
From €5245EUR$5,850USD£4,482GBP
- Report
- August 2026
- 182 Pages
Global
From €5245EUR$5,850USD£4,482GBP
- Report
- August 2026
- 564 Pages
Global
From €5245EUR$5,850USD£4,482GBP
- Report
- August 2026
- 413 Pages
Global
From €5245EUR$5,850USD£4,482GBP
- Report
- August 2026
- 276 Pages
Global
From €5245EUR$5,850USD£4,482GBP
- Report
- August 2026
- 257 Pages
Global
From €5245EUR$5,850USD£4,482GBP
- Report
- August 2026
- 208 Pages
Global
From €5245EUR$5,850USD£4,482GBP
- Report
- August 2026
- 349 Pages
Global
From €5245EUR$5,850USD£4,482GBP
- Report
- August 2026
- 193 Pages
Global
From €5245EUR$5,850USD£4,482GBP
- Report
- August 2026
- 504 Pages
Global
From €5245EUR$5,850USD£4,482GBP
- Report
- August 2026
- 368 Pages
Global
From €5245EUR$5,850USD£4,482GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more